{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:45:00Z","timestamp":1791999900583,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,29]],"date-time":"2027-07-29T00:00:00Z","timestamp":1816819200000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["T32 ES007091"],"award-info":[{"award-number":["T32 ES007091"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["R01 ES028668"],"award-info":[{"award-number":["R01 ES028668"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.dmd.2026.100351","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:03:59Z","timestamp":1782774239000},"page":"100351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic exogenous probe strategy using ezetimibe-glucuronide effectively identifies metabolic dysfunction\u2013associated steatohepatitis"],"prefix":"10.1016","volume":"54","author":[{"given":"Dominique O.","family":"Farrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7016-8058","authenticated-orcid":false,"given":"Kayla L.","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4215-9434","authenticated-orcid":false,"given":"Joseph L.","family":"Jilek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6059-2074","authenticated-orcid":false,"given":"Paxton A.","family":"Sample","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jailyn M.","family":"Izu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4501-775X","authenticated-orcid":false,"given":"Mina M.","family":"Alaaldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max M.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangwoo","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-An","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-5488","authenticated-orcid":false,"given":"Mark","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumathy","family":"Mathialagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lazzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6159-039X","authenticated-orcid":false,"given":"Aiden-Hung P.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"Messenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9217-9866","authenticated-orcid":false,"given":"Ahmad Omid","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Akhbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6013-4809","authenticated-orcid":false,"given":"Carolina","family":"S\u00e4ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Klimecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-1839","authenticated-orcid":false,"given":"Mary F.","family":"Paine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Billheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2400-8252","authenticated-orcid":false,"given":"Geoffrey","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Ghaderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J.","family":"Cherrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9 suppl","key":"10.1016\/j.dmd.2026.100351_bib1","first-page":"S159","article-title":"Management strategies for metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"30","author":"Alkhouri","year":"2024","journal-title":"Am J Manag Care"},{"issue":"18","key":"10.1016\/j.dmd.2026.100351_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186420","article-title":"MASH: the nexus of metabolism, inflammation, and fibrosis","volume":"135","author":"Steinberg","year":"2025","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.dmd.2026.100351_bib3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jceh.2022.12.005","article-title":"The growing economic and clinical burden of nonalcoholic steatohepatitis (NASH) in the United States","volume":"13","author":"Younossi","year":"2023","journal-title":"J Clin Exp Hepatol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100351_bib4","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s12325-024-03085-4","article-title":"Understanding MASH: an examination of progression and clinical outcomes by disease severity in the TARGET-NASH database","volume":"42","author":"Luthra","year":"2025","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100351_bib5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/LVT.0000000000000688","article-title":"Steatotic liver disease is the dominant indication for liver transplantation in both Europe and the United States: trends and outcomes in the past 2 decades","volume":"32","author":"Younossi","year":"2025","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.dmd.2026.100351_bib6","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12916-025-04320-7","article-title":"Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Arita","year":"2025","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.dmd.2026.100351_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s13679-024-00597-6","article-title":"Nutritional strategies for battling obesity-linked liver disease: the role of medical nutritional therapy in metabolic dysfunction-associated steatotic liver disease (MASLD) management","volume":"14","author":"Simancas-Racines","year":"2025","journal-title":"Curr Obes Rep"},{"issue":"6","key":"10.1016\/j.dmd.2026.100351_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.dmd.2026.100351_bib9","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41587-025-02828-0","article-title":"Wegovy approved for MASH","volume":"43","year":"2025","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100351_bib10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.dmd.2026.100351_bib11","first-page":"130","article-title":"Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values","volume":"25","author":"Amarapurkar","year":"2004","journal-title":"Trop Gastroenterol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100351_bib12","first-page":"153","article-title":"Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)","volume":"20","author":"Fierbinteanu-Braticevici","year":"2011","journal-title":"J Gastrointestin Liver Dis"},{"issue":"4","key":"10.1016\/j.dmd.2026.100351_bib13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00042737-200604000-00015","article-title":"Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations","volume":"18","author":"Foucher","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100351_bib14","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dmd.2026.100351_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2013.07.042","article-title":"Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease","volume":"60","author":"Cusi","year":"2014","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100351_bib16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2893.2006.00730.x","article-title":"Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin","volume":"13","author":"Trocme","year":"2006","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.dmd.2026.100351_bib17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MPG.0000000000001136","article-title":"Plasma cytokeratin-18 level as a novel biomarker for liver fibrosis in children with nonalcoholic fatty liver disease","volume":"63","author":"Mandelia","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"8","key":"10.1016\/j.dmd.2026.100351_bib18","first-page":"1237","article-title":"Adipokines in non-alcoholic fatty liver disease: are we on the road toward new biomarkers and therapeutic targets?","volume":"11","author":"Francisco","year":"2022","journal-title":"Biology (Basel)"},{"issue":"12 suppl 11","key":"10.1016\/j.dmd.2026.100351_bib19","first-page":"12","article-title":"Analysis of baseline PRO-C3 and ELF components in patients with MASH\/MASLD and MASH cirrhosis and correlations between change in PRO-C3 and ELF in resmetirom-treated patients from the MAESTRO-NASH trial","volume":"21","year":"2025","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"5","key":"10.1016\/j.dmd.2026.100351_bib20","first-page":"939","article-title":"Serum YKL-40 levels as a non-invasive potential biomarker for liver fibrosis patients: a systematic review and meta-analysis","volume":"54","author":"Li","year":"2025","journal-title":"Iran J Public Health"},{"issue":"5","key":"10.1016\/j.dmd.2026.100351_bib21","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1111\/dom.16233","article-title":"Identification of growth differentiation factor 15 as an early predictive biomarker for metabolic dysfunction-associated steatohepatitis: a nested case\u2013control study of UK Biobank proteomic data","volume":"27","author":"Wang","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.dmd.2026.100351_bib22","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.1542\/hpeds.2023-007462","article-title":"Receiver operating characteristic (ROC) curves: the basics and beyond","volume":"14","author":"Chang","year":"2024","journal-title":"Hosp Pediatr"},{"issue":"4","key":"10.1016\/j.dmd.2026.100351_bib23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1124\/dmd.121.000413","article-title":"Strategies to diagnose nonalcoholic steatohepatitis: a novel approach to take advantage of pharmacokinetic alterations","volume":"50","author":"Marie","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100351_bib24","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dmd.2026.100351_bib25","series-title":"Considerations for including tissue biopsies in clinical trials; draft guidance for industry, investigators, institutions, and institutional review boards; availability","first-page":"1173","year":"2025"},{"issue":"5","key":"10.1016\/j.dmd.2026.100351_bib26","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/s41401-021-00832-z","article-title":"NASH: regulatory considerations for clinical drug development and U.S. FDA approval","volume":"43","author":"Harvey","year":"2022","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"10.1016\/j.dmd.2026.100351_bib28","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/j.1476-5381.2011.01672.x","article-title":"Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells","volume":"165","author":"Fahrmayr","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100351_bib29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmd.2026.100351_bib30","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/jpet.114.220764","article-title":"Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis","volume":"352","author":"Dzierlenga","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"1-3","key":"10.1016\/j.dmd.2026.100351_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2009.04.002","article-title":"Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats","volume":"613","author":"Fisher","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100351_bib32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/dmd.111.041095","article-title":"Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis","volume":"40","author":"Hardwick","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100351_bib33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.119.257600","article-title":"Quantitative contribution of six major transporters to the hepatic uptake of drugs: \"SLC-phenotyping\" using primary human hepatocytes","volume":"370","author":"Bi","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2026.100351_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2026.117455","article-title":"Detection and quantification of ezetimibe and its major glucuronide in patients with hepatic impairment via liquid chromatography-tandem mass spectrometry","volume":"275","author":"Farrera","year":"2026","journal-title":"J Pharm Biomed Anal"},{"issue":"5","key":"10.1016\/j.dmd.2026.100351_bib35","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/cpt.2107","article-title":"Assessing transporter-mediated natural product-drug interactions via in vitro-in vivo extrapolation: clinical evaluation with a probe cocktail","volume":"109","author":"Nguyen","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100351_bib36","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3390\/pharmaceutics14030620","article-title":"Clinical pharmacokinetic assessment of kratom (Mitragyna speciosa), a botanical product with opioid-like effects, in healthy adult participants","volume":"14","author":"Tanna","year":"2022","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.dmd.2026.100351_bib37","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1124\/dmd.116.071415","article-title":"Nonalcoholic steatohepatitis modulates membrane protein retrieval and insertion processes","volume":"44","author":"Dzierlenga","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2026.100351_bib38","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.freeradbiomed.2006.02.015","article-title":"Oxidative stress and Mrp2 internalization","volume":"40","author":"Sekine","year":"2006","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"10.1016\/j.dmd.2026.100351_bib39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbrc.2010.07.069","article-title":"Oxidative stress is a triggering factor for LPS-induced Mrp2 internalization in the cryopreserved rat and human liver slices","volume":"399","author":"Sekine","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"10.1016\/j.dmd.2026.100351_bib40","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.cgh.2020.11.005","article-title":"Clinical utility of change in nonalcoholic fatty liver disease activity score and change in fibrosis in NAFLD","volume":"19","author":"Tamaki","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100351_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16127","article-title":"Accuracy of non-invasive imaging techniques for the diagnosis of MASH in patients with MASLD: a systematic review","volume":"45","author":"Cathcart","year":"2025","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.dmd.2026.100351_bib42","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000033","article-title":"The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance","volume":"7","author":"Gill","year":"2023","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.dmd.2026.100351_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0232-1513(87)80077-4","article-title":"Relation between renal and hepatic excretion of drugs: III. Comparison of various methods reducing the renal or hepatic excretory capacity of rats","volume":"31","author":"Fleck","year":"1987","journal-title":"Exp Pathol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100351_bib44","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.xphs.2017.04.053","article-title":"Effect of liver disease on hepatic transporter expression and function","volume":"106","author":"Thakkar","year":"2017","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100351_bib45","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/03602532.2017.1293682","article-title":"Glucuronidation: driving factors and their impact on glucuronide disposition","volume":"49","author":"Yang","year":"2017","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.dmd.2026.100351_bib46","article-title":"The role of uptake and efflux transporters in the disposition of glucuronide and sulfate conjugates","volume":"12","author":"J\u00e4rvinen","year":"2021","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100351_bib47","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/FPC.0b013e3282fe9a2c","article-title":"Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1","volume":"18","author":"Oswald","year":"2008","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1016\/j.dmd.2026.100351_bib48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/dmd.122.001038","article-title":"Renal transporter alterations in patients with chronic liver diseases: nonalcoholic steatohepatitis, alcohol-associated, viral hepatitis, and alcohol-viral combination","volume":"51","author":"Frost","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100351_bib49","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MAJ.0b013e3182831740","article-title":"Decreased renal organic anion transporter 3 expression in type 1 diabetic rats","volume":"347","author":"Phatchawan","year":"2014","journal-title":"Am J Med Sci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100351_bib50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/pharmaceutics16020285","article-title":"Dysregulation of the mRNA expression of human renal drug transporters by proinflammatory cytokines in primary human proximal tubular epithelial cells","volume":"16","author":"Tsang","year":"2024","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.dmd.2026.100351_bib51","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1124\/dmd.111.041012","article-title":"Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease","volume":"39","author":"Hardwick","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100351_bib52","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.taap.2013.01.022","article-title":"Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease","volume":"268","author":"Lake","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100351_bib53","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/dmd.115.065979","article-title":"CYP3A activity and expression in nonalcoholic fatty liver disease","volume":"43","author":"Woolsey","year":"2015","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:53:37Z","timestamp":1791996817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0090955626006203"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100351","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic exogenous probe strategy using ezetimibe-glucuronide effectively identifies metabolic dysfunction\u2013associated steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100351"}}